A robust, target-driven, cell-based assay for checkpoint kinase 1 inhibitors |
| |
Authors: | Ish Tsuyoshi Sootome Hiroshi King Alastair J Suda Mikiya Noro Nobuhiro Yamashita Keizo Noumi Takato Ishii Tsuyoshi |
| |
Institution: | GlaxoSmithKline K.K., Tsukuba-shi Ibaraki, Japan. hiroshi_sootome@merck.com |
| |
Abstract: | Checkpoint kinase 1 (Chk1), a serine/threonine kinase, plays an important role in DNA damage checkpoint control and is an attractive target for cancer treatment. To develop a Chk1-specific cell-based assay, stable clones were established in which Chk1 kinase domain fused at its N-terminus with p53 through 4 tandem repeats of Gly-Gly-Gly-Gly-Ser was expressed in an inducible manner. Chk1 kinase specificity of the phosphorylation of fused p53 was confirmed by the experiments with a kinase-inactive Chk1. Only in the presence of an inducer molecule was phosphorylation of p53 at Ser-15 in the stable clones induced. Furthermore, its assay performance proved acceptable for high-throughput screening applications, judging from the Z' factor values (> 0.77). Finally, the cell-based assay thus established yielded structure-activity relationship data for a small set of test inhibitors of Chk1 within cells. Collectively, these results demonstrate that the established cell-based assay provides a novel and highly sensitive cellular platform for Chk1 inhibitor discovery. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|